Compare BIIB & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | LII |
|---|---|---|
| Founded | 1978 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 17.7B |
| IPO Year | 1991 | 1999 |
| Metric | BIIB | LII |
|---|---|---|
| Price | $175.19 | $496.18 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 12 |
| Target Price | $177.40 | ★ $603.36 |
| AVG Volume (30 Days) | ★ 2.0M | 472.7K |
| Earning Date | 10-30-2025 | 01-28-2026 |
| Dividend Yield | N/A | ★ 1.03% |
| EPS Growth | N/A | ★ 12.46 |
| EPS | 10.97 | ★ 23.67 |
| Revenue | ★ $10,065,900,000.00 | $5,345,300,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | $7.34 |
| P/E Ratio | ★ $15.86 | $21.37 |
| Revenue Growth | ★ 4.77 | 3.77 |
| 52 Week Low | $110.04 | $443.19 |
| 52 Week High | $185.17 | $689.44 |
| Indicator | BIIB | LII |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 50.81 |
| Support Level | $169.24 | $497.54 |
| Resistance Level | $180.79 | $525.00 |
| Average True Range (ATR) | 5.04 | 13.87 |
| MACD | -1.57 | 2.89 |
| Stochastic Oscillator | 42.85 | 52.08 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.